Rahaman SO. TRPV4 ion channel is a novel regulator of dermal myofibroblast differentiation.
-Scleroderma is a multisystem fibroproliferative disease with no effective medical treatment. Myofibroblasts are critical to the fibrogenic tissue repair process in the skin and many internal organs. Emerging data support a role for both matrix stiffness, and transforming growth factor ␤1 (TGF␤1), in myofibroblast differentiation. Transient receptor potential vanilloid 4 (TRPV4) is a mechanosensitive ion channel activated by both mechanical and biochemical stimuli. The objective of this study was to determine the role of TRPV4 in TGF␤1-and matrix stiffness-induced differentiation of dermal fibroblasts. We found that TRPV4 channels are expressed and functional in both human (HDF) and mouse (MDF) dermal fibroblasts. TRPV4 activity (agonist-induced Ca 2ϩ influx) was induced by both matrix stiffness and TGF␤1 in dermal fibroblasts. TGF␤1 induced expression of TRPV4 proteins in a dose-dependent manner. Genetic ablation or pharmacological antagonism of TRPV4 channel abrogated Ca 2ϩ influx and both TGF␤1-induced and matrix stiffness-induced myofibroblast differentiation as assessed by 1) ␣-smooth muscle actin expression/incorporation into stress fibers, 2) generation of polymerized actin, and 3) expression of collagen-1. We found that TRPV4 inhibition abrogated TGF␤1-induced activation of AKT but not of Smad2/3, suggesting that the mechanism by which profibrotic TGF␤1 signaling in dermal fibroblasts is modified by TRPV4 may be through nonSmad pathways. Altogether, these data identify a novel reciprocal functional link between TRPV4 activation and TGF␤1 signals regulating dermal myofibroblast differentiation. These findings suggest that therapeutic inhibition of TRPV4 activity may provide a targeted approach to the treatment of scleroderma. TRPV4; calcium influx; dermal myofibroblast differentiation; matrix stiffness FIBROSIS, a form of scarring, is a common pathological process in the lung, heart, kidney, vasculature, skin, and liver (5, 15, 36, 40, 47, 48) . Fibrosis is responsible for nearly half of deaths in the developed world, yet, there is no effective anti-fibrotic therapy (54) . Fibroblasts-to-myofibroblasts transition is a key event in maintaining tissue homeostasis and in both physiological and pathological tissue repair processes. In fibrotic and scarring pathologies like scleroderma, sustained and exacerbated differentiation of fibroblasts into myofibroblasts is an essential component of the synthesis and deposition of extracellular matrix (ECM) responsible for excessive scarring or fibrosis (5, 15, 47, 48) . Fibroblasts directly respond to changes to their surrounding mechanical environment during myofibroblast differentiation (48, 51) . For example, in response to acute or chronic lung injury, myofibroblasts accumulate in high matrix stiffness areas known as fibroblastic foci (13, 47, 52) . The contribution of mechanical stress in augmenting dermal myofibroblast activity has also been shown experimentally by stretching dermal wounds in mice, which results in increased scar formation (38, 52) . Although both mechanical and biochemical signals are essential for optimal fibroblast differentiation, the precise mechanisms and the identity of plasma membrane mechanosensors by which differentiation signals are transduced and propagated are unknown. Compelling evidence indicates that cell adhesion, integrin, and focal adhesion kinase (FAK) signaling are critical for fibroblast differentiation in vitro and in vivo (14, 25, 38, 48, (51) (52) (53) . Although FAK has been shown to transmit mechanotransduction signals that induce dermal fibroblast differentiation (53) , the identity of a mechanotransduction receptor/channel upstream of FAK activation, and the molecular mechanisms by which mechanical signals are transduced intracellularly to drive fibroblast differentiation, remain unknown. Recently, we found that TRPV4, a mechanosensitive, Ca 2ϩ -permeable, plasma membrane channel, mediates myofibroblast differentiation of lung fibroblasts and contributes to the development of pulmonary fibrosis in a mouse model (39) . TRPV4 has not previously been known to be involved in dermal myofibroblast differentiation, nor has the mechanism of its involvement in this process been determined.
TGF␤1 is the most well-studied profibrotic mediator of both myofibroblast differentiation in vitro, and of fibrogenesis of many organs including skin (2, 4, 5, 40, 47, 55) . TGF␤1 signals through a plasma membrane receptor complex of TGF␤1-receptor type I and II resulting in downstream activation of either the transcription factors Smad2/3 pathways or through Smad-independent pathways that include c-Jun NH 2 -terminal kinase, p38 kinases, FAK, phosphatidylinositol 3-kinase (PI3K), and Rho GTPases. Both Smad and non-Smad pathways have been linked to myofibroblast differentiation and fibrosis (2, 4, 55) . TGF␤1 also has beneficial/homeostatic roles in regulating immune suppression, inflammation, cell growth, and tissue maintenance in various pathophysiological conditions (2, 4, 55). Therefore, any therapeutic approach that directly targets TGF␤1 is likely to have serious, perhaps fatal, side effects. However, a specific molecular strategy that targeted the fibrogenic signals of the TGF␤1 pathway without interfering with the beneficial roles of TGF␤1 would have considerable therapeutic potential. The potential cross-talk of matrix stiffness and soluble TGF␤1 in TRPV4 signaling in dermal fibroblasts may provide such an opportunity.
TRPV4, a member of the TRP superfamily, is ubiquitously expressed in various cell types including fibroblasts. TRPV4 is activated by a wide range of chemical and physical stimuli including changes in osmolarity, warm temperatures, mechanical stresses, UVB exposure, growth factors, and metabolites of arachidonic acid (12, 22, 24, 32, 37, 39, 50, 57) . Intriguingly, TRPV4 channels has been shown to be activated by cyclical stretching of cells, or by mechanical forces applied to ␤1 integrins in cell surface (27, 45) . Recently, TRPV4 was shown to function as a mechanosensor in response to dynamic loading in chondrocytes (37) . In addition to its transmembrane structure, TRPV4 contains a number of potential regulatory domains and protein-interaction sites, including PI3K and Src homology 2 (SH2) recognition domains, putative protein kinase C (PKC) phosphorylation sites, putative PDZ domains, and an NH 2 -terminal ankyrin repeat region (9, 13) . Various gain-and loss-of-function mutations in TRPV4 have been linked to human diseases including skeletal dysplasia and sensory and motor neuropathies (3, 8, 18) . TRPV4 is linked to multiple physiological and pathological functions including sheer stress detection in blood vessels, joint diseases, skeletal malformations, pain response, and osteoclast differentiation control in bone (7, 16, 17, 19, 26, 28) . In mice, TRPV4 deficiency is associated with altered blood pressure and vasodilatory responses, vascular permeability, bladder function, lung injury, and lung fibrosis (3, 8 -10, 13, 18, 29, 39) . However, a potential role of TRPV4 mechanosensing in dermal myofibroblast differentiation has not been reported. In this study we sought to determine the expression and mechanosensing role of TRPV4 calcium channels in dermal myofibroblast differentiation. Results presented here identify a novel regulatory role for TRPV4 in dermal myofibroblast differentiation induced by both TGF␤1 and pathophysiological matrix stiffness.
MATERIALS AND METHODS
Animal and cell culture. TRPV4 knockout (TRPV4 KO) mice on a C57BL/6 background were originally generated by Dr. M. Suzuki, Department of Pharmacology, Jichi Medical University, Tochigi, Japan (31) . We acquired TRPV4 KO mice from Dr. D. X. Zhang, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI (56) . Congenic wild-type (WT) C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA). All experiments on mice were performed in accordance with the Institutional Animal Care and Use Committee guidelines and guidelines approved by the University of Maryland review committee. Mice were housed under pathogen-free conditions with controlled temperature and humidity, and with food and water available ad libitum.
Primary normal adult human dermal fibroblasts (HDFs) were purchased from ATCC (Manassas, VA), and were used within passages 3-8 for all experiments. Primary normal mouse dermal fibroblasts (MDFs) were derived from skin biopsies from armpit of 8-to 10-wk-old WT and TRPV4 KO mice as described previously (21) . Both HDFs and MDFs were maintained in Minimum Essential Media (MEM) supplemented with 10% fetal bovine serum (FBS), and penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA). Cells were incubated at 37°C/5% CO 2 and subcultured at 70% confluence. For isolation of MDFs, mouse skin tissue was washed with HBSS (with Ca 2ϩ ), minced, and treated with collagenase (2.5 mg/ml) for 30 min with continuous shaking at 37°C/5% CO 2. Digested tissues were spun down, resuspended in MEM 15% FBS, and mechanically dissociated by pipetting up and down 8 -10 times. The fibroblasts isolated from the tissue were then seeded in culture flasks. Medium was replaced with MEM 10% FBS every 48 h thereafter. Although the cultures initially contained a variety of cell types including macrophages, keratinocytes, and adipocytes, the procedure and culture conditions selectively promote fibroblast growth. Repeated trypsinization and culturing of cells in MEM removes keratinocytes. The polyhedral and cuboidal shaped keratinocytes can be easily distinguished from elongated and spindle-shaped fibroblasts. We checked for the presence of fibroblast markers such as ␣-smooth muscle actin (␣-SMA) and incorporation of ␣-SMA into F-actin stress fibers by immune/phalloidin double staining. For all experiments, HDFs and MDFs were seeded on collagen-coated (10 g/ml) surfaces in MEM 1% FBS for 24 h followed by treatment with TGF␤1 (R&D Systems, Minneapolis, MN) in serum-free medium containing 1% bovine serum albumin (BSA).
Reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was extracted from HDFs and MDFs using RNeasy micro kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RT-PCR was carried out under a standard protocol using the following TRPV4 primers: forward, 5=-GGCACCTATCGTCACCACTC-3=, and reverse, 5=-TCCTCATCAGTTAGGCGTTTC-3=; and mouse TRPV4 primers: forward, 5=-GAGTCCTCAGTAGTGCCTGG-3=, and reverse, 5=-CAACAAGAAGGAGAGCAGTC-3=.
Western blot analysis. After treatment with TGF␤1, with or without inhibitors (TRPV4 inhibitor: GSK219; and PI3K inhibitors: LY294002 and wortmannin), cells were lysed in modified RIPA buffer (50 mM Tris·HCl, 150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) with protease and phosphatase inhibitors. Cell lysates were resolved on 10% SDSpolyacrylamide gels and transferred to polyvinylidene difluoride membranes. Immunoblotting was performed using the following primary antibodies: rabbit anti-phospho-Smad2/3, rabbit anti-Smad2/3, rabbit anti-phospho-Akt, rabbit anti-Akt (1:2,000; Cell Signaling, Beverly, MA); mouse anti-␣-SMA (1:20,000; Sigma, St. Louis, MO); goat anti-collagen type I (1:700; EMD Millipore, Billerica, MA); rabbit anti-TRPV4 (1:700; Alomone, Jerusalem, Israel), goat anti-␤-actin (EMD Millipore); rabbit anti-GAPDH (1:3,000; Santa Cruz, Dallas, TX), followed by incubation with secondary antibodies goat anti-mouse, goat anti-rabbit, and donkey anti-goat (1:5,000; Jackson ImmunoResearch, West Grove, PA). Immunoreactive bands were visualized using an enhanced chemiluminescence system (UVP Biospectrum, Upland, CA).
In vitro myofibroblast differentiation assay. To assess myofibroblast differentiation in MDFs and HDFs, cells were seeded on hydrogels (0.5 and 8 kPa) (Matrigen Life Technologies, Brea, CA) or coverglasses. Cells were maintained in MEM 1% FBS for 24 h. Cells were then incubated in serum-free MEM supplemented with 1% BSA with or without TGF␤1 (2 or 5 ng/ml) and TRPV4 antagonists GSK2193874 (GSK219), and HC-067047 (HC) (Sigma) or vehicle, for 48 h and then processed for immunofluorescence staining of myofibroblast markers.
Immunofluorescence staining analysis. Immunofluorescence staining was performed for colocalization of the structural elements of dermal fibroblasts as previously described (55) . Cells adhered on coverglasses or hydrogels were fixed with 3% paraformaldehyde, permeabilized with 0.1% Triton X-100 and blocked with 3% BSA/ PBS. To examine ␣-SMA incorporation into cytoskeletal fibers or TRPV4 protein expression, samples were incubated with anti-␣-SMA (1:400) or anti-TRPV4 (1:50), followed by incubation with goat anti-mouse Alexa Fluor 488 (1:300; Thermo Fisher Scientific). F-actin fibers were stained using Alexa Fluor 594 phalloidin (1:300; Thermo Fisher Scientific). Cells were then mounted using Prolong diamond antifade reagent with DAPI (Thermo Fisher Scientific). Immunofluorescence intensity was quantified using ImageJ software (NIH), and the results are presented as Integrated Density or Int Density (the product of area and mean gray value).
Measurement of intracellular calcium. Changes in intracellular calcium in dermal fibroblasts were detected by the FlexStation system using a FLIPR calcium 5 Assay Kit (Molecular Devices, Sunnyvale, CA). Briefly, HDFs or MDFs (10,000 cells/well in 1% MEM) were treated for 48 h with or without TGF␤1 at 37°C, 5% CO 2. Cells were then incubated with FLIPR kit reagents (Calcium 5 dye in 1X HBSS solution containing 20 mM HEPES and 2.5 mM probenecid) for 45 min at 37°C. Cells were incubated with vehicle or TRPV4 antagonist, GSK219, for 45 min at 37°C and then the 96-well plate was transferred to the FlexStation for measuring intracellular calcium change (Ca 2ϩ influx). Calcium influx was induced by the TRPV4 agonist, GSK1016790A (GSK101), in fibroblasts that were pretreated with vehicle or GSK219, and recorded by measuring ⌬F/F (Max-Min); data are shown as relative fluorescence units (RFU). The effect of matrix stiffness on Ca 2ϩ influx in MDFs and HDFs was assayed using hydrogels of different stiffness (1, 8 , and 25 kPa) bound to 96-well glass bottom plates (39) . Measurement of Ca 2ϩ influx was performed using the FlexStation system.
Statistics. All data are expressed as means Ϯ SE as indicated below. Statistical comparisons between control and experimental groups were performed with the Student's t-test or one-way ANOVA using SigmaPlot or Prism software; P Ͻ 0.05 was considered significant.
RESULTS
TRPV4 protein is expressed and functional channels occur in both primary human and murine dermal fibroblasts. To determine whether TRPV4 channels are required in dermal myofibroblast differentiation, we first examined TRPV4 expression in primary normal human and mouse dermal fibroblasts (HDFs and MDFs). We detected expression of TRPV4 RNA in HDFs using reverse transcription polymerase chain reaction (RT-PCR) analysis (Fig. 1A) , and we detected expression of TRPV4 protein in HDFs in the presence or absence of TGF␤1 by immunoblotting ( Results shown are means Ϯ SE from 3 independent experiments (*P Ͻ 0.05, **P Ͻ 0.01 for TGF␤1-treated cells vs. untreated, n ϭ 3, t-test). G: immunoblots show TRPV4 protein expression in wild-type (WT) MDFs, which is absent in TRPV4 KO MDFs. Triplicate samples were loaded for analysis and actin was used as loading control. For experiments described in this figure, cells were seeded on collagen-coated (10 g/ml) plastic plates.
crease in total cellular TRPV4 protein expression (Fig. 1C) . Similarly, we detected expression of TRPV4 RNA in MDFs using RT-PCR analysis (Fig. 1D) , and we detected expression of TRPV4 protein in MDFs in response to TGF␤1 doses by immunoblotting (Fig. 1E) . Stimulation of MDFs with TGF␤1 for 48 h produced a dose-dependent increase in total cellular TRPV4 protein expression (Fig. 1F) . We validated the TRPV4 antibody by immunoblot analysis showing TRPV4 protein expression in wild-type (WT) MDFs, which is absent in TRPV4 KO MDFs (Fig. 1G) . To confirm the presence of functional Ca 2ϩ -permeable TRPV4 channel in dermal fibroblasts, we compared Ca 2ϩ influx in primary mouse dermal fibroblasts (MDFs) from TRPV4 knockout (TRPV4 KO) and congenic wild-type (WT) mice over a range of concentrations of a selective TRPV4 agonist, GSK101 (1-1,000 nM) (10). GSK101-induced Ca 2ϩ influx was undetectable in TRPV4 KO fibroblasts even in the presence of a 200-fold excess of GSK101 (EC 50 ϭ 5 nM) (Fig. 2, A-C influx was inhibited in a concentration-dependent manner (IC 50 ϭ 32 nM) by pretreatment with the selective small molecule TRPV4 antagonist, GSK219 (46) (Fig. 2, F and G) . As expected from work in human lung fibroblasts (HLFs) (39), the TRPV4-mediated rise in intracellular Ca 2ϩ was entirely dependent on the presence of external Ca 2ϩ in HDFs (Fig. 2H ). TGF␤1 stimulation can cause calcium wave activity in HLFs that is dependent on both an external influx of Ca 2ϩ and on the release of Ca 2ϩ from internal stores (34) . However, we found that TRPV4-dependent Ca of the sarco/endoplasmic reticulum calcium transport ATPase (SERCA) (SD208 for TGF␤RI, Xesto for IP3R, RyD for RyR, and CPA for SERCA) (Fig. 2H) . These results suggest that the mobilization of internally released Ca 2ϩ is not necessary for TRPV4-elicited Ca 2ϩ influx in HDFs. These results indicate that both human and murine dermal fibroblasts express functional TRPV4 channels capable of mediating calcium influx resulting in a rise in intracellular calcium.
TGF␤1 stimulation and increased matrix stiffness potentiates TRPV4-mediated Ca 2ϩ influx in dermal fibroblasts. Emerging data support a role for both a mechanical signal, e.g., matrix stiffness, and a biochemical signal, e.g., TGF␤1, in fibroblast differentiation during the fibrotic process in multiple organs (14, 37, 48, 51, 52) . However, the mechanism by which the matrix stiffness signal is transduced intracellularly and the identities of plasma membrane mechanosensors by which myofibroblast differentiation signals are propagated are unknown. Recently, we discovered that TRPV4 is required for both TGF␤1-and matrix stiffness-induced lung fibroblast differentiation and pulmonary fibrosis development in mice (39) . Herein, we observed that pretreatment of HDFs with TGF␤1 caused a~2-fold increase in GSK101-induced Ca 2ϩ influx compared with untreated controls, and this response was inhibited by the TRPV4 antagonist, GSK219 (Fig. 3, A-C) . In addition, we found that TRPV4 channel activity (as measured by agonist-induced Ca 2ϩ influx) was increased in a matrix stiffness-dependent manner when cells were plated on stiffer matrices within the pathophysiological range (1-25 kPa) (Fig.  3D) . Antagonism of the TRPV4 channel by GSK219, or genetic deletion of TRPV4 in MDFs, selectively abrogated matrix stiffness-induced Ca 2ϩ influx (Fig. 3D) . Since internal stiffness of cells is known to be modulated by stiffness of the matrix (43), it is possible that fibroblasts seeded on hydrogels (1, 8, or 25 kPa) generate reduced cellular stiffness. In contrast, cells may experience increased stiffness when seeded on plastic (stiffness Ͼ 1 GPa). As TRPV4 is a matrix stiffnesssensitive channel, the increased Ca 2ϩ influx noted in fibroblasts seeded on plastic compared with 1, 8, or 25 kPa stiffness gels is possibly due to differences in differential activation of TRPV4 channels. A recent report from our group showed that Ca 2ϩ influx in human lung fibroblasts was comparatively lower (Ͻ60) on 1, 8, or 25 kPa gel than on plastic (39), which Fig. 2 , is augmented by pretreatment (48 h) of HDFs with increasing doses of TGF␤1 (as indicated) and abrogated by GSK219. A23 and untreated HDFs were used as positive and negative controls, respectively. C: the quantified results shown are means Ϯ SE from 3 independent experiments (*P Ͻ 0.05, **P Ͻ 0.01 for TGF␤1 cells vs. untreated, and ###P Ͻ 0.001 for GSK219-treated cells vs. untreated). All experiments were repeated 3 times in quadruplicate. D: WT MDFs, TRPV4 KO MDFs, and HDFs were plated (10,000 cells per well) on collagen-coated (10 g/ml) hydrogels with varying degrees of stiffness (1, 8 , and 25 kPa) under vehicle-treated or GSK219-treated (5 M) conditions. GSK101-induced (10 nM) Ca 2ϩ influx, measured as in Fig.  2 , is increased by stiffness and abrogated by GSK219 or TRPV4 deficiency. **P Ͻ 0.01 for cells grown on stiff (8 kPa and 25 kPa) hydrogels vs. soft (1 kPa), ***P Ͻ 0.001 for GSK219-treated vs. vehicle treated cells grown on 25 kPa hydrogels; n ϭ 3, t-test. E: both HDFs and MDFs were plated on collagen-coated (10 g/ml) hydrogels with varying degrees of stiffness (0.5 and 8 kPa). Representative fluorescence micrographs (original magnification, ϫ40) showing that TRPV4 expression is increased by matrix stiffness (8 kPa vs. 0.5 kPa) in both HDFs and MDFs. F: quantified results are expressed as means Ϯ SE. **P Ͻ 0.01, ***P Ͻ 0.001 for stiff (8 kPa) vs. soft (0.5 kPa) HDFs. n ϭ 10 cells per condition, 1-way ANOVA. supports our data here. Together, these results indicate that TRPV4 activity (Ca 2ϩ influx) is potentiated by both TGF␤1 stimulation and matrix stiffness in dermal fibroblasts. To understand the mechanism whereby increased matrix stiffness can augment TRPV4 activity in dermal fibroblasts we determined if TRPV4 abundance in dermal fibroblasts increased in response to increasing matrix stiffness. For this, both HDFs and MDFs were plated on collagen-coated (10 g/ml) hydrogels with varying degrees of stiffness (0.5 and 8 kPa). We found that TRPV4 protein expression is increased by matrix stiffness (8 kPa vs. 0.5 kPa) in both HDFs and MDFs (Fig. 3,  E and F) .
TRPV4 is required for TGF␤1-induced primary normal dermal myofibroblast differentiation. TRPV4 has recently been linked to the differentiation of chondrocytes, osteoclasts, cardiac fibroblasts, and lung fibroblasts (1, 26, 35, 39) . To determine whether TRPV4 contributes to dermal myofibroblast differentiation, we compared TGF␤1-induced myofibroblast differentiation (using ␣-SMA incorporation into stress fibers and expression of collagen-1 protein as an index of myofibroblast differentiation) in primary dermal fibroblasts from TRPV4 KO and congenic WT mice. TGF␤1-induced dermal myofibroblast differentiation was reduced by 60% (n ϭ 15 cells/group; ###P Ͻ 0.001) in TRPV4 KO fibroblasts compared with WT (Fig. 4, A and B) . In addition, we found that TGF␤1-induced expression of both collagen-1 and ␣-SMA proteins were reduced in WT MDFs compared with TRPV4 KO (Fig. 4, C and D) . These results indicate that TGF␤1-induced dermal myofibroblast differentiation is dependent on TRPV4. Next, we tested whether blocking TRPV4 channel activity with selective small-molecule antagonists abrogates TGF␤1-induced human dermal myofibroblast differentiation. We found that TRPV4 antagonism by its selective antagonist, HC (9, 46) , abrogated TGF␤1-induced myofibroblast differentiation by~60% compared with untreated controls, as shown by ␣-SMA protein expression, and by incorporation of ␣-SMA in stress fibers (Fig. 4 , E and F; n ϭ 15 cells/condition, **P Ͻ 0.01, ***P Ͻ 0.001 with or without HC). Furthermore, we demonstrated that TRPV4 antagonism by GSK219, a recently identified novel TRPV4 antagonist (9, 46) , abrogated TGF␤1-induced human dermal myofibroblast differentiation by~70% compared with untreated controls, as shown by expression of collagen-1 and ␣-SMA protein (Fig. 4 , G and H; **P Ͻ 0.01, ***P Ͻ 0.001; and ##P Ͻ 0.01 with or without GSK219). Taken together, these results indicate that TRPV4 calcium channel activity is required for TGF␤1-induced dermal myofibroblast differentiation.
Matrix stiffness-induced dermal myofibroblast differentiation is dependent on TRPV4 channels. In the context of tissue fibrosis, increased matrix stiffness is well documented, and numerous studies have shown that changes in matrix rigidity can modulate many cellular functions including myofibroblast differentiation (14, 24, 48, 51, 52) . However, the molecular mechanism by which matrix stiffness-induced mechanotransduction signals participate in myofibroblast differentiation has remained elusive. To determine whether TRPV4 is involved in matrix stiffness-induced dermal myofibroblast differentiation, we compared myofibroblast differentiation potential of both HDFs and MDFs grown on collagen-coated hydrogels of various degrees of stiffness. We observed increased myofibroblast differentiation when fibroblasts were grown on 8 kPa hydrogels (pathophysiological stiffness comparable to fibrotic lung tissue) (25, 44, 48) compared with 0.5 kPa (normal lung tissue) as determined by ␣-SMA expression and its incorporation into stress fibers. We found that blocking TRPV4 channels with GSK219 in HDFs (Fig. 5, A-C) , or genetic deletion of TRPV4 in MDFs (Fig. 5, D-F) , abrogated the capacity of a stiff matrix to induce myofibroblast differentiation. These results indicate that TRPV4-dependent Ca 2ϩ influx is required for matrix stiffness-dependent myofibroblast differentiation.
TRPV4 modulates profibrotic TGF␤1 actions in a Smadindependent but PI3K-AKT-dependent manner. Given that the profibrotic functions of TGF␤1 are regulated by both Smaddependent and independent signals (2, 4, 55), we assessed the capacity of TRPV4 activity to modulate TGF␤1-induced phosphorylation of Smad2/3 in HDFs. Treatment with TGF␤1 caused an increase in phosphorylation of Smad2/3 as expected, but this response was not inhibited in TRPV4 KO MDFs (Fig.  6A) . However, we found that PI3K-AKT signal, a non-Smad pathway, is involved in dermal myofibroblast differentiation induced by TGF␤1 (Fig. 6, B-G) . We examined the role of TRPV4 in PI3K activation in dermal fibroblasts. We found that in TGF␤1-stimulated MDFs (Fig. 6, B and C) or HDFs (Fig. 6 , D and E) activation of PI3K (as determined by the phosphorylation status of AKT) was reduced~2-to 3-fold by the loss of TRPV4 activity (TRPV4 KO fibroblasts or GSK219-pretreated HDFs). We also found that in TGF␤1-stimulated HDFs (Fig. 6 , F and G) expression level of ␣-SMA and collagen-1 protein was attenuated by 2-to 3-fold in the presence of PI3K inhibitors, LY or WO. In this study we found that both LY and WO inhibited basal expression level of collagen-1 protein in HDFs. All together these results suggest that TRPV4 activity may regulate TGF␤1-dependent myofibroblast differentiation independent of Smad2/3 activation.
DISCUSSION
The key findings of this study are 1) functional TRPV4 calcium channels are expressed in primary normal human and murine dermal fibroblasts, 2) TRPV4-mediated Ca 2ϩ influx is upregulated in dermal fibroblasts exposed to both TGF␤1 and pathophysiological matrix stiffness, and 3) TRPV4-dependent Ca 2ϩ influx potentiates TGF␤1-induced dermal myofibroblast differentiation under conditions of matrix stiffness comparable to fibrotic tissue. Furthermore, we provide evidence that TRPV4 inhibition by genetic deficiency or pharmacologic antagonism abrogates TGF␤1-induced phosphorylation of AKT, but not Smad2/3 in both human and mouse dermal fibroblasts.
TRPV4 proteins are ubiquitously expressed in various cell types and tissues, and TRPV4 activity is known to be regulated by both mechanical and soluble factors (9, 13) . Given the existence of other TRP family members, it is remarkable that mice deficient only in TRPV4 exhibit modified vasodilatory responses, osmosensing, neurological function, and bone development, and develop ventilation-induced lung edema (3, 8 -10, 13, 18, 31, 46) . A recent study by our group showed that TRPV4 null mice are protected from developing bleomycininduced lung fibrosis (39) . Many human diseases including skeletal and nerve disorders have been linked to mutations in TRPV4 as a result of gain-or loss-of-function responses (3, 8, 18) . Although the importance of the role of TGF␤1, matrix stiffness, and mechanosignaling in dermal myofibroblast differentiation and fibrosis has been recognized (53), the role of TRPV4 mechanosensing in dermal myofibroblast differentiation has not been previously reported. In the current study, we found that TRPV4 protein expression and its channel activity (Ca 2ϩ influx) were upregulated by chronic TGF␤1 exposure in dermal fibroblasts. These results suggest a potential mechanism by which activity of TRPV4 channel can be augmented during scleroderma pathogenesis. Intriguingly, there are emerging data supporting a role for Ca 2ϩ -initiated signals in myofibroblast differentiation and function (11, 34) ; however, the identity of the Ca 2ϩ channel involved, and the mechanisms by which Ca 2ϩ signals promote these effects, are poorly understood. It has been shown that TGF␤1 stimulation of lung fibroblasts can generate an oscillating calcium signal, which is dependent on ER pumps/receptors and on TGF␤R kinase activity (34) . However, we found that TRPV4-dependent Ca 2ϩ influx in dermal fibroblasts was uniphasic and persistent (Ͼ3 min), and was independent of ER pumps/receptors and of TGF␤RI kinase activity. These results are consistent with the reported TRPV4-dependent Ca 2ϩ signal in human lung fibroblasts, and suggest that mobilization of internally released Ca 2ϩ is not required for TRPV4-elicited cytoplasmic Ca 2ϩ influx in dermal fibroblasts. Both in vitro and in vivo studies have provided substantial evidence on the contribution of TGF␤1 signals in promoting fibrosis, and in particular, myofibroblast differentiation (5, 15, 36, 40, 47, 48) . However, a growing body of data now supports a role for both a mechanical signal, e.g., matrix stiffness, and a biochemical signal, e.g., TGF␤1, in optimal myofibroblast differentiation (14, 25, 48, 51, 52) . Furthermore, it is recently well recognized that the stiffened ECM in various fibrotic diseases including scleroderma may augment activation of fibroblasts and subsequent generation of myofibroblasts by chronically releasing active TGF␤1 (14) . Conversely, TGF␤1-dependent activation of fibroblasts and generation of contractile and synthetic myofibroblasts can cause increases in matrix stiffness and mechanical responses of the ECM (14, 25, 48, 51, 52) . These observations are relevant to the pathophysiology of wound healing and fibrosis, as injuries that trigger fibrotic responses to increase tissue stiffness may subsequently influence overall differentiation of fibroblasts into myofibroblasts in a positive feed-forward manner. The question of how different signaling events, such as matrix stiffness and TGF␤1, might cooperate and/or integrate to affect myofibroblast differentiation remains to be determined.
The elasticity (Young's modulus) of most plastics and glass used for cell culture is around 1 GPa and 70 GPa, respectively. However, the Young's modulus of mammalian cells (e.g., fibroblasts) is~1 kPa. Therefore, the natural cell environment is~1,000,000 times more elastic than cell culture vessels. Although in vitro studies using cells grown on matrix proteincoated plastic or glass surfaces with infinite stiffness have provided important insights regarding fibroblast differentiation, these approaches have serious limitations with regard to recapitulating the physiological tissue context and matrix stiffness. In our strategy, cells were plated on collagen-coated polyacrylamide gels with physiologically relevant stiffness, which enabled us to decipher the effect of either normal (soft) or fibrotic (stiff) dermal tissue matrix on TRPV4-dependent fibroblast differentiation. We investigated whether TRPV4-integrated mechanical (matrix stiffness) and soluble (TGF␤1) signals mediate dermal myofibroblast differentiation by utilizing collagen-coated polyacrylamide gels of varying stiffness (30). We found that the TRPV4 channel activity (agonistinduced Ca 2ϩ influx) was potentiated when cells were plated on stiffer matrices within the pathophysiological range seen in diseased/fibrotic dermal tissue. The inhibition of TRPV4 channel activity (by genetic deficiency or pharmacological antagonism by three selective TRPV4 antagonists) significantly abrogated TGF␤1-induced enhancement of myofibroblast differentiation when cells were plated on collagen-coated plastics. These data demonstrated that dermal myofibroblast differentiation was sensitive to TRPV4 channel activity. Importantly, inhibition of TRPV4 function in human dermal fibroblasts by selective pharmacological antagonists, or in primary dermal fibroblasts isolated from TRPV4 null mice, resulted in the loss of ability of these cells to undergo TGF␤1-induced myofibroblast differentiation on collagen-coated hydrogels of pathophysiologically relevant stiffness. These results demonstrated that TRPV4 function was required in this process. The results of this study suggest a pathogenic sequence of profibrotic signaling in scleroderma that integrates mechanical (matrix stiffness) and biochemical soluble signals (TGF␤1) to induce myofibroblast differentiation.
TGF␤1 utilizes both canonical (Smad) and noncanonical (nonSmad) intracellular signaling pathways to modulate downstream cellular responses (2, 4, 55) . Here, we provide evidence that absence of TRPV4 function (loss of expression or loss of Ca 2ϩ channel activity) does not affect TGF␤1-induced Smad2/3 phosphorylation in dermal fibroblasts. However, in TGF␤1-stimulated human or mouse dermal fibroblasts, activation of PI3K (as determined by the phosphorylation status of AKT) was reduced~2-fold by the absence of TRPV4 activity, suggesting that the mechanism by which profibrotic TGF␤1 signaling in dermal fibroblasts is modified by TRPV4 may be through noncanonical pathways. Importantly, inhibition of PI3K function in human dermal fibroblasts by selective inhibitors resulted in reduced expression of collagen-1 protein under both basal and TGF␤1-induced conditions. These results all together suggest a possible role of a feed-forward loop involving PI3K and TRPV4 signaling in TRPV4 sensitization, which could be a critical component of pathogenic fibroblast signaling (20) .
Furthermore, utilizing both plastic wells and variable stiffness hydrogels, we showed that inhibition of TRPV4 activity abrogated the extensive actin polymerization otherwise seen upon TGF␤1-induced myofibroblast differentiation. In view of the fact that TGF␤1-induced actin polymerization facilitates MRTF-A release from actin monomers, thereby allowing for MRTF-A nuclear translocation, which induces ␣-SMA transcription during lung myofibroblast differentiation (6, 41) , it will be interesting to determine if the mechanism by which TRPV4 potentiates TGF␤1-induced dermal myofibroblast differentiation is through actin polymerization-dependent nuclear translocation of MRTF-A. Recently, Seth et al. (42) revealed that TRPV4 activation protects against nonalcoholic fatty liver disease, thus alerting against the consequences of global blocking of TRPV4 that can promote hepatotoxicity. Therefore, a suitable balanced approach will be required to inhibit TRPV4 by systemic application of TRPV4 blockers to treat fibrotic or other disorders.
In summary, we report a novel role of TRPV4 in dermal myofibroblast differentiation. We show that TRPV4 calcium channel activity modulates profibrotic TGF␤1 actions in a Smad-independent manner, and augments myofibroblast differentiation. In addition, our data show that TRPV4-elicited Ca 2ϩ influx and myofibroblast differentiation are sensitized through interactions of cells with a matrix whose stiffness lies within the pathophysiological range. Importantly, TRP channel-targeted small molecule inhibitors are currently in preclinical or early phase clinical trials for other disorders (33) . Since this work identifies a previously unrecognized reciprocal functional link between TRPV4 activation and TGF␤1 signals in dermal fibroblasts, results of this work may lead to a novel therapeutic approach to the treatment of scleroderma and wound healing diseases. 
